Fenwick & West represented Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company that is providing trustworthy and actionable answers that fundamentally improve patient care when current diagnostic tests are uncertain, in its underwritten public offering of 5,750,000 shares of common stock, including 750,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares, at a price to the public of $10.25 per share. The net proceeds to Veracyte from the offering were approximately $55.1 million, after deducting underwriting discounts and commissions and estimated offering expenses.
Leerink Partners and William Blair acted as joint book-running managers for the offering and BTIG acted as lead manager.
The Fenwick transaction team included Robert Freedman, Ran Ben-Tzur, Jennifer Hitchcock and Michael Ohta.